Abstract
Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Current Vascular Pharmacology
Title: Visfatin/PBEF and Atherosclerosis-Related Diseases
Volume: 8 Issue: 1
Author(s): Theodosios D. Filippatos, Harpal S. Randeva, Christos S. Derdemezis, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Abstract: Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Export Options
About this article
Cite this article as:
Filippatos D. Theodosios, Randeva S. Harpal, Derdemezis S. Christos, Elisaf S. Moses and Mikhailidis P. Dimitri, Visfatin/PBEF and Atherosclerosis-Related Diseases, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226679
DOI https://dx.doi.org/10.2174/157016110790226679 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Continue the Great Journey of Success!]
Current Molecular Medicine Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Comparison of Amniotic Fluid Index and Single Deepest Vertical Pocket
Current Women`s Health Reviews Current Progress in Molecular Responses to Acidosis in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Editorial: Look for Changes in 2016
Current Molecular Medicine A Comprehensive Review on Perfusion Method Development for Bone Marrow Collection and Stem Cell Transplantation
Current Stem Cell Research & Therapy The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy for Pituitary Tumors
Current Gene Therapy Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety 3D-QSAR analysis of MCD inhibitors by CoMFA and CoMSIA
Combinatorial Chemistry & High Throughput Screening Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
Current Drug Safety Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Proposed Benchmark Methods for Analyzing Acai (Euterpe oleraceae Mart.)
The Natural Products Journal The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Non-Steroidal Anti-Inflammatory Drugs (Selective and Non-Selective) on the Treatment of Periodontal Diseases
Current Pharmaceutical Design Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews